Nautilus Biotechnology vs 10x Genomics
Side-by-side comparison of AI visibility scores, market position, and capabilities
Nautilus Biotechnology is building a single-molecule proteomics platform to map and quantify the full human proteome at a scale and sensitivity previously impossible.
About
Nautilus Biotechnology is a proteomics company founded in 2016 and publicly listed on Nasdaq, developing a revolutionary platform for analyzing proteins at single-molecule resolution. While genomics has transformed medicine through DNA and RNA sequencing, the proteome is the actual functional layer of biology where drug targets, disease biomarkers, and therapeutic mechanisms operate. Nautilus is building a platform that can identify and quantify thousands of proteins simultaneously from tiny biological samples using a fluorescence-based single-molecule detection approach without requiring mass spectrometry. The platform promises to enable proteomics studies at a scale and depth comparable to what next-generation sequencing delivered to genomics, unlocking new insights into disease biology and drug development. Nautilus is in the instrument development phase and targets pharmaceutical research, clinical diagnostics, and academic biology. The company has raised over $250M and is building manufacturing capabilities for a planned commercial instrument launch that could define a new era in proteomics research.
Leading single-cell genomics platform; $642M FY2025 revenue. Chromium and Visium spatial platforms power cell-type discovery in oncology, neuroscience, and immunology.
About
10x Genomics was founded in 2012 in Pleasanton, California by Serge Saxonov, Ben Hindson, and Kevin Ness. The company developed the Chromium platform for single-cell RNA sequencing (scRNA-seq), enabling researchers to analyze gene expression across thousands of individual cells simultaneously—a capability that transformed cell biology, immunology, and cancer research. The Visium Spatial Gene Expression platform extended this to map gene expression within intact tissue architecture.\n\n10x Genomics' instruments and consumables are used by leading academic research centers, pharmaceutical companies, and translational medicine teams to profile the cellular composition of tumors, map the nervous system, characterize immune responses, and develop cell therapies. The company reported full-year 2025 revenue of $642.8 million, up from $610.8 million in 2024, and guides to $600–$625 million for 2026 amid cautious biotech funding conditions.\n\nThe company is transitioning toward a broader multi-omics portfolio including ATAC-seq, protein detection, and spatial multi-omics, while defending market position against competition from Parse Biosciences, Vizgen, and others. Despite near-term funding headwinds in academic markets, 10x Genomics remains a foundational infrastructure provider for the cell atlas era of biology.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.